From infection niche to therapeutic target: the intracellular lifestyle of Mycobacterium tuberculosis

References

1. World Health Organization Global Tuberculosis Report France: 2018
   [Google Scholar]
2. Soeroto AY, Lestari BW, Santoso P, Chaidir L, Andriyoko B et al. Evaluation of Xpert MTB-RIF guided diagnosis and treatment of rifampicin-resistant tuberculosis in Indonesia: a retrospective cohort study. PLoS One 2019; 14:e0213017
   [Google Scholar]
3. Hmama Z, Peña-Díaz S, Joseph S, Av-Gay Y. Immunoevasion and immunosuppression of the macrophage by Mycobacterium tuberculosis . Immunol Rev 2015; 264:220–232
   [Google Scholar]
4. Kroesen VM, Groschel MI, Martinson N, Zumla A, Maeurer M et al. Non-Steroidal anti-inflammatory drugs as Host-Directed therapy for tuberculosis: a systematic review. Front Immunol 2017; 8:772
   [Google Scholar]
5. Padmapriyadarsini C, Bhavani PK, Natrajan M, Ponnuraja C, Kumar H et al. Evaluation of metformin in combination with rifampicin containing antituberculosis therapy in patients with new, smear-positive pulmonary tuberculosis (METRIF): study protocol for a randomised clinical trial. BMJ Open 2019; 9:e024363
   [Google Scholar]
6. Simões MF, Ottoni CA, Antunes A. Mycogenic metal nanoparticles for the treatment of mycobacterioses. Antibiot 2020; 9:
   [Google Scholar]
7. Jafari A, Nagheli A, Foumani AA, Soltani B, Goswami R. The role of metallic nanoparticles in inhibition of Mycobacterium tuberculosis and enhances phagosome maturation into the infected macrophage. Oman Med J 2020; 35:e194
   [Google Scholar]
8. Tăbăran A-F, Matea CT, Mocan T, Tăbăran A, Mihaiu M et al. Silver nanoparticles for the therapy of tuberculosis. Int J Nanomedicine 2020; 15:2231–2258
   [Google Scholar]
9. Jensen MS, Bainton DF. Temporal changes in pH within the phagocytic vacuole of the polymorphonuclear neutrophilic leukocyte. J Cell Biol 1973; 56:379–388
   [Google Scholar]
10. Poirier V, Av-Gay Y. Intracellular growth of bacterial pathogens: the role of secreted effector proteins in the control of phagocytosed microorganisms. Microbiol Spectr. 2015; 3:
    [Google Scholar]
11. Denzin LK, Cresswell P. Hla-Dm induces clip dissociation from MHC class II alpha beta dimers and facilitates peptide loading. Cell 1995; 82:155–165
    [Google Scholar]
12. Vieira O V, Botelho RJ, Grinstein S. Phagosome maturation: aging gracefully. Biochem J . 2002 Sep 15; 366:689–704
    [Google Scholar]
13. Fratti RA, Chua J, Vergne I, Deretic V. Mycobacterium tuberculosis glycosylated phosphatidylinositol causes phagosome maturation arrest. Proc Natl Acad Sci 2003; 100:5437–5442
    [Google Scholar]
14. Deretic V, Singh S, Master S, Harris J, Roberts E et al. Mycobacterium tuberculosis inhibition of phagolysosome biogenesis and autophagy as a host defence mechanism. Cell Microbiol 2006; 8:719–727
    [Google Scholar]
15. Fratti RA, Backer JM, Gruenberg J, Corvera S, Deretic V. Role of phosphatidylinositol 3-kinase and Rab5 effectors in phagosomal biogenesis and mycobacterial phagosome maturation arrest. J Cell Biol 2001; 154:631–644
    [Google Scholar]
16. Hu C, Ahmed M, Melia TJ, Sollner TH, Mayer T et al. Fusion of cells by flipped SNAREs. Science 2003; 300:1745–1749
    [Google Scholar]
17. Rink J, Ghigo E, Kalaidzidis Y, Zerial M. Rab conversion as a mechanism of progression from early to late endosomes. Cell 2005; 122:735–749
    [Google Scholar]
18. Balderhaar HJk, Ungermann C. CORVET and HOPS tethering complexes - coordinators of endosome and lysosome fusion. J Cell Sci 2013; 126:1307–1316 [View Article]
    [Google Scholar]
19. Jordens I, Fernandez-Borja M, Marsman M, Dusseljee S, Janssen L et al. The Rab7 effector protein RILP controls lysosomal transport by inducing the recruitment of dynein-dynactin motors. Curr Biol 2001; 11:1680–1685
    [Google Scholar]
20. Harrison RE, Bucci C, Vieira OV, Schroer TA, Grinstein S. Phagosomes fuse with late endosomes and/or lysosomes by extension of membrane protrusions along microtubules: role of Rab7 and RILP. Mol Cell Biol 2003; 23:6494–6506 [View Article][PubMed]
    [Google Scholar]
21. Zulauf KE, Sullivan JT, Braunstein M. The SecA2 pathway of Mycobacterium tuberculosis exports effectors that work in concert to arrest phagosome and autophagosome maturation. PLoS Pathog 2018; 14:1–29
    [Google Scholar]
22. Vergne I, Chua J, Lee H-H, Lucas M, Belisle J et al. Mechanism of phagolysosome biogenesis block by viable Mycobacterium tuberculosis . Proc Natl Acad Sci U S A 2005; 102:4033–4038
    [Google Scholar]
23. Walburger A, Koul A, Ferrari G, Nguyen L, Prescianotto-Baschong C et al. Protein kinase G from pathogenic mycobacteria promotes survival within macrophages. Science 2004; 304:1800–1804
    [Google Scholar]
24. Wong D, Bach H, Sun J, Hmama Z, Av-Gay Y. Mycobacterium tuberculosis protein tyrosine phosphatase (PtpA) excludes host vacuolar-H+-ATPase to inhibit phagosome acidification. Proc Natl Acad Sci 2011; 108:19371–19376
    [Google Scholar]
25. Christoforidis S, Miaczynska M, Ashman K, Wilm M, Zhao L et al. Phosphatidylinositol-3-Oh kinases are Rab5 effectors. Nat Cell Biol 1999; 1:249–252
    [Google Scholar]
26. Chua J, Deretic V. Mycobacterium tuberculosis reprograms waves of phosphatidylinositol 3-phosphate on phagosomal organelles. J Biol Chem 2004; 279:36982–36992
    [Google Scholar]
27. Rajaram MVS, Arnett E, Azad AK, Guirado E, Ni B et al. M. tuberculosis-initiated human mannose receptor signaling regulates macrophage recognition and vesicle trafficking by FcRgamma-Chain, Grb2, and SHP-1. Cell Rep 2017; 21:126–140
    [Google Scholar]
28. Fernandez-Soto P, Bruce AJE, Fielding AJ, Cavet JS, Tabernero L. Mechanism of catalysis and inhibition of Mycobacterium tuberculosis SapM, implications for the development of novel antivirulence drugs. Sci Rep 2019; 9:10315
    [Google Scholar]
29. Fernandez-Soto P, Cavet JS, Tabernero L. Expression and purification of soluble recombinant SapM from Mycobacterium tuberculosis. Protein Expr Purif 2020; 174:105663
    [Google Scholar]
30. Park H-J, Lee SJ, Kim S-H, Han J, Bae J et al. Il-10 inhibits the starvation induced autophagy in macrophages via class I phosphatidylinositol 3-kinase (PI3K) pathway. Mol Immunol 2011; 48:720–727
    [Google Scholar]
31. Harris J, De Haro SA, Master SS, Keane J, Roberts EA et al. T Helper 2 Cytokines Inhibit Autophagic Control of Intracellular Mycobacterium tuberculosis . Immunity 2007; 27:505–517
    [Google Scholar]
32. Roberts EA, Chua J, Kyei GB, Deretic V. Higher order Rab programming in phagolysosome biogenesis. J Cell Biol. 2006/09/18 2006; 174:923–929
    [Google Scholar]
33. Chandra P, Ghanwat S, Matta SK, Yadav SS, Mehta M et al. Mycobacterium tuberculosis Inhibits RAB7 Recruitment to Selectively Modulate Autophagy Flux in Macrophages. Sci Rep 2015; 5:1–10
    [Google Scholar]
34. van der Woude AD, Stoop EJM, Stiess M, Wang S, Ummels R et al. Analysis of SecA2-dependent substrates in Mycobacterium marinum identifies protein kinase G (PknG) as a virulence effector. Cell Microbiol 2014; 16:280–295
    [Google Scholar]
35. Hinchey J, Jeon BY, Alley H, Chen B, Goldberg M et al. Lysine auxotrophy combined with deletion of the SecA2 gene results in a safe and highly immunogenic candidate live attenuated vaccine for tuberculosis. PLoS One. 2011; 6:e15857
    [Google Scholar]
36. Saikolappan S, Estrella J, Sasindran SJ, Khan A, Armitige LY et al. The fbpA/sapM double knock out strain of Mycobacterium tuberculosis is highly attenuated and immunogenic in macrophages. PLoS One 2012; 7:e36198
    [Google Scholar]
37. Vilchèze C, Hartman T, Weinrick B, Jacobs WRJ. Mycobacterium tuberculosis is extraordinarily sensitive to killing by a vitamin C-induced Fenton reaction. Nat Commun 1881; 2013:4
    [Google Scholar]
38. Vilchèze C, Kim J, Jacobs WR. Vitamin C potentiates the killing of Mycobacterium tuberculosis by the first-line tuberculosis drugs isoniazid and rifampin in mice. Antimicrob Agents Chemother 2018; 62:
    [Google Scholar]
39. Maniak M, Rauchenberger R, Albrecht R, Murphy J, Gerisch G. Coronin involved in phagocytosis: dynamics of particle-induced relocalization visualized by a green fluorescent protein tag. Cell 1995; 83:915–924
    [Google Scholar]
40. Ferrari G, Langen H, Naito M, Pieters J. A coat protein on phagosomes involved in the intracellular survival of mycobacteria. Cell 1999; 97:435–447
    [Google Scholar]
41. Nguyen L, Pieters J. The Trojan horse: survival tactics of pathogenic mycobacteria in macrophages. Trends Cell Biol 2005; 15:269–276
    [Google Scholar]
42. Hestvik ALK, Av-Gay Y, Hmama Z. Mycobacterial manipulation of the host cell. FEMS Microbiol Rev 2005; 29:1041–1050
    [Google Scholar]
43. Vergne I, Chua J, Deretic V. Mycobacterium tuberculosis phagosome maturation arrest: selective targeting of PI3P-dependent membrane trafficking. Traffic 2003; 4:600–606
    [Google Scholar]
44. Jayachandran R, Sundaramurthy V, Combaluzier B, Mueller P, Korf H et al. Survival of mycobacteria in macrophages is mediated by coronin 1-dependent activation of calcineurin. Cell 2007; 130:37–50
    [Google Scholar]
45. Trimble WS, Grinstein S. Tb or not TB: calcium regulation in mycobacterial survival. Cell 2007; 130:12–14
    [Google Scholar]
46. Poirier V, Bach H, Av-Gay Y. Mycobacterium tuberculosis Promotes Anti-apoptotic Activity of the Macrophage by PtpA Protein-dependent Dephosphorylation of Host GSK3α. J Biol Chem 2014; 289:29376–29385
    [Google Scholar]
47. Bach H, Papavinasasundaram KG, Wong D, Hmama Z, Av-Gay Y. Mycobacterium tuberculosis Virulence Is Mediated by PtpA Dephosphorylation of Human Vacuolar Protein Sorting 33B. Cell Host Microbe 2008; 3:316–322
    [Google Scholar]
48. Chao J, Wong D, Zheng X, Poirier V, Bach H et al. Protein kinase and phosphatase signaling in Mycobacterium tuberculosis physiology and pathogenesis. Biochim Biophys Acta - Proteins Proteomics 1804; 2010:620–627
    [Google Scholar]
49. Bach H, Wong D, Av-Gay Y. Mycobacterium tuberculosis PtkA is a novel protein tyrosine kinase whose substrate is PtpA. Biochem J 2009; 420:155–162
    [Google Scholar]
50. Zhou P, Wong D, Li W, Xie J, Av-Gay Y. Phosphorylation of Mycobacterium tuberculosis protein tyrosine kinase A PtkA by Ser/Thr protein kinases. Biochem Biophys Res Commun 2015
    [Google Scholar]
51. Wong D, Li W, Chao JD, Zhou P, Narula G et al. Protein tyrosine kinase, PtkA, is required for Mycobacterium tuberculosis growth in macrophages. Sci Rep 2018; 8:155
    [Google Scholar]
52. Bach H, Sun J, Hmama Z, Av-Gay Y. Mycobacterium avium subsp. paratuberculosis PtpA is an endogenous tyrosine phosphatase secreted during infection. Infect Immun 2006; 74:6540–6546
    [Google Scholar]
53. Poirier V. Molecular Analysis of Mycobacterium tuberculosis Infection of Human Macrophages: The Role of Protein Tyrosine Phosphatase A The University Of British Columbia; 2015
    [Google Scholar]
54. Hestvik ALK, Hmama Z, Av-Gay Y. Kinome analysis of host response to mycobacterial infection: a novel technique in proteomics. Infect Immun 2003; 71:5514–5522
    [Google Scholar]
55. Wang J, Ge P, Qiang L, Tian F, Zhao D et al. The mycobacterial phosphatase PtpA regulates the expression of host genes and promotes cell proliferation. Nat Commun 2017; 8:
    [Google Scholar]
56. Manger M, Scheck M, Prinz H, von Kries JP, Langer T et al. Discovery of Mycobacterium tuberculosis Protein Tyrosine Phosphatase A (MptpA) inhibitors based on natural products and a fragment-based approach. ChemBioChem 2005; 6:1749–1753
    [Google Scholar]
57. Stehle T, Sreeramulu S, Lohr F, Richter C, Saxena K et al. The apo-structure of the low molecular weight protein-tyrosine phosphatase A (MptpA) from Mycobacterium tuberculosis allows for better target-specific drug development. J Biol Chem 2012; 287:34569–34582
    [Google Scholar]
58. Rawls KA, Lang PT, Takeuchi J, Imamura S, Baguley TD et al. Fragment-based discovery of selective inhibitors of the Mycobacterium tuberculosis protein tyrosine phosphatase PtpA. Bioorg Med Chem Lett 2009; 19:6851–6854
    [Google Scholar]
59. Mascarello A, Mori M, Chiaradia-Delatorre LD, Menegatti ACO, Delle Monache F et al. Discovery of Mycobacterium tuberculosis protein tyrosine phosphatase B (PtpB) inhibitors from natural products. PLoS One 2013; 8:e77081 [View Article][PubMed]
    [Google Scholar]
60. Dutta NK, He R, Pinn ML, He Y, Burrows F et al. Mycobacterial protein tyrosine phosphatases A and B inhibitors augment the bactericidal activity of the standard anti-tuberculosis regimen. ACS Infect Dis 2016; 2:231–239
    [Google Scholar]
61. Mascarello A, Chiaradia LD, Vernal J, Villarino A, Guido RVC et al. Inhibition of Mycobacterium tuberculosis tyrosine phosphatase PtpA by synthetic chalcones: kinetics, molecular modeling, toxicity and effect on growth. Bioorg Med Chem 2010; 18:3783–3789
    [Google Scholar]
62. Margenat M, Labandera A-M, Gil M, Carrion F, Purificação M et al. New potential eukaryotic substrates of the mycobacterial protein tyrosine phosphatase PtpA: hints of a bacterial modulation of macrophage bioenergetics state. Sci Rep 2015; 5:8819
    [Google Scholar]
63. Savalas LRT, Furqon BRN, Asnawati D, ’Ardhuha J, Sedijani P et al. Cis-2 and trans-2-eisocenoic fatty acids are novel inhibitors for Mycobacterium tuberculosis Protein tyrosine phosphatase A. Acta Biochim Pol 2020; 67:219–223
    [Google Scholar]
64. Mori M, Sammartino JC, Costantino L, Gelain A, Meneghetti F et al. An overview on the potential antimycobacterial agents targeting serine/threonine protein kinases from Mycobacterium tuberculosis . Curr Top Med Chem 2019; 19:646–661
    [Google Scholar]
65. Nagpal P, Jamal S, Singh H, Ali W, Tanweer S et al. Long-range replica exchange molecular dynamics guided drug repurposing against tyrosine kinase PtkA of Mycobacterium tuberculosis . Sci Rep 2020; 10:4413
    [Google Scholar]
66. Lu J, Holmgren A. The thioredoxin antioxidant system. Free Radic Biol Med 2014; 66:75–87
    [Google Scholar]
67. Lin K, O’Brien KM, Trujillo C, Wang R, Wallach JB et al. Mycobacterium tuberculosis thioredoxin reductase is essential for thiol redox homeostasis but plays a minor role in antioxidant defense. PLOS Pathog 2016; 12:e1005675
    [Google Scholar]
68. Av-Gay Y, Everett M. The eukaryotic-like Ser/Thr protein kinases of Mycobacterium tuberculosis . Trends Microbiol 2000; 8:238–244
    [Google Scholar]
69. Scherr N, Honnappa S, Kunz G, Mueller P, Jayachandran R et al. Structural basis for the specific inhibition of protein kinase G, a virulence factor of Mycobacterium tuberculosis . Proc Natl Acad Sci U S A 2007; 104:12151–12156
    [Google Scholar]
70. Tiwari D, Singh RK, Goswami K, Verma SK, Prakash B et al. Key residues in Mycobacterium tuberculosis protein kinase G play a role in regulating kinase activity and survival in the host. J Biol Chem 2009; 284:27467–27479
    [Google Scholar]
71. Cowley S, Ko M, Pick N, Chow R, Downing KJ et al. The Mycobacterium tuberculosis protein serine/threonine kinase PknG is linked to cellular glutamate/glutamine levels and is important for growth in vivo . Mol Microbiol 2004; 52:1691–1702
    [Google Scholar]
72. O’Hare HM, Duran R, Cervenansky C, Bellinzoni M, Wehenkel AM et al. Regulation of glutamate metabolism by protein kinases in mycobacteria. Mol Microbiol 2008; 70:1408–1423
    [Google Scholar]
73. Bhattacharyya N, Nkumama IN, Newland-Smith Z, Lin L-Y, Yin W et al. An Aspartate-Specific solute-binding protein regulates protein kinase G activity to control glutamate metabolism in mycobacteria. MBio 2018; 9:
    [Google Scholar]
74. Khan MZ, Bhaskar A, Upadhyay S, Kumari P, Rajmani RS et al. Protein kinase G confers survival advantage to Mycobacterium tuberculosis during latency-like conditions. J Biol Chem 2017; 292:16093–16108
    [Google Scholar]
75. Paroha R, Chourasia R, Mondal R, Chaurasiya SK. PknG supports mycobacterial adaptation in acidic environment. Mol Cell Biochem 2018; 443:69–80
    [Google Scholar]
76. Gil M, Lima A, Rivera B, Rossello J, Urdaniz E et al. New substrates and interactors of the mycobacterial serine/threonine protein kinase PknG identified by a tailored interactomic approach. J Proteomics 2019; 192:321–333
    [Google Scholar]
77. Baros SS, Blackburn JM, Soares NC. Phosphoproteomic approaches to discover novel substrates of mycobacterial Ser/Thr protein kinases. Mol Cell Proteomics 2020; 19:233–244
    [Google Scholar]
78. Chakraborti PK, Matange N, Nandicoori VK, Singh Y, Tyagi JS et al. Signalling mechanisms in mycobacteria. Tuberculosis 2011; 91:432–440
    [Google Scholar]
79. Walburger A, Koul A, Ferrari G, Nguyen L, Prescianotto-Baschong C et al. Protein kinase G from pathogenic mycobacteria promotes survival within macrophages. Science 2004; 304:1800–1804
    [Google Scholar]
80. F-L W, Liu Y, Zhang H-N, Jiang H-W, Cheng L et al. Global profiling of PknG interactions using a human proteome microarray reveals novel connections with CypA. Proteomics 2018; 18:e1800265
    [Google Scholar]
81. Pradhan G, Shrivastva R, Mukhopadhyay S. Mycobacterial PknG targets the Rab7L1 signaling pathway to inhibit phagosome-lysosome fusion. J Immunol 2018; 201:1421–1433
    [Google Scholar]
82. MacLeod DA, Rhinn H, Kuwahara T, Zolin A, Di Paolo G et al. RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson’s disease risk. Neuron 2013; 77:425–439
    [Google Scholar]
83. Hegymegi-Barakonyi B, Szekely R, Varga Z, Kiss R, Borbely G et al. Signalling inhibitors against Mycobacterium tuberculosis-early days of a new therapeutic concept in tuberculosis. Curr Med Chem 2008; 15:2760–2770
    [Google Scholar]
84. Chen D, Ma S, He L, Yuan P, She Z et al. Sclerotiorin inhibits protein kinase G from Mycobacterium tuberculosis and impairs mycobacterial growth in macrophages. Tuberculosis 2017; 103:37–43
    [Google Scholar]
85. Mesguiche V, Parsons RJ, Arris CE, Bentley J, Boyle FT et al. 4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2. Bioorg Med Chem Lett 2003; 13:217–222
    [Google Scholar]
86. Kidwai S, Bouzeyen R, Chakraborti S, Khare N, Das S et al. NU-6027 Inhibits Growth of Mycobacterium tuberculosis by Targeting Protein Kinase D and Protein Kinase G. Antimicrob Agents Chemother 2019; 63:
    [Google Scholar]
87. Arris CE, Boyle FT, Calvert AH, Curtin NJ, Endicott JA et al. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. J Med Chem 2000; 43:2797–2804
    [Google Scholar]
88. Charrier J-D, Miller A, Kay DP, Brenchley G, Twin HC et al. Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors. J Med Chem 2011; 54:2341–2350
    [Google Scholar]
89. Kanehiro Y, Tomioka H, Pieters J, Tatano Y, Kim H et al. Identification of novel mycobacterial inhibitors against mycobacterial protein kinase G. Front Microbiol 2018; 9:1517
    [Google Scholar]
90. Zabludoff SD, Deng C, Grondine MR, Sheehy AM, Ashwell S et al. Azd7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther 2008; 7:2955–2966
    [Google Scholar]
91. Matsubara S, Li G, Takeda K, Loader JE, Pine P et al. Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyperresponsiveness. Am J Respir Crit Care Med 2006; 173:56–63
    [Google Scholar]
92. Nguyen L, Walburger A, Houben E, Koul A, Muller S et al. Role of protein kinase G in growth and glutamine metabolism of Mycobacterium bovis BCG. J Bacteriol 2005; 187:5852–5856
    [Google Scholar]
93. Rieck B, Degiacomi G, Zimmermann M, Cascioferro A, Boldrin F et al. PknG senses amino acid availability to control metabolism and virulence of Mycobacterium tuberculosis . PLoS Pathog 2017; 13:e1006399 [View Article][PubMed]
    [Google Scholar]
94. Freeman BA, O’Donnell VB, Schopfer FJ. The discovery of nitro-fatty acids as products of metabolic and inflammatory reactions and mediators of adaptive cell signaling. Nitric oxide Biol Chem 2018; 77:106–111
    [Google Scholar]
95. Gil M, Grana M, Schopfer FJ, Wagner T, Denicola A et al. Inhibition of Mycobacterium tuberculosis PknG by non-catalytic rubredoxin domain specific modification: reaction of an electrophilic nitro-fatty acid with the Fe-S center. Free Radic Biol Med 2013; 65:150–161
    [Google Scholar]
96. Khan MZ, Kaur P, Nandicoori VK. Targeting the messengers: serine/threonine protein kinases as potential targets for antimycobacterial drug development. IUBMB Life 2018; 70:889–904
    [Google Scholar]
97. Gagné F, Stress O. Oxidative stress. In Gagné FBT-BE. editor Biochemical Ecotoxicology Principals and Methods Oxford: Academic Press; 2014 pp 103–115
    [Google Scholar]
98. Bielski BH, Arudi RL, Sutherland MW. A study of the reactivity of HO2/O2- with unsaturated fatty acids. J Biol Chem 1983; 258:4759–4761
    [Google Scholar]
99. McCord JM, Fridovich I, dismutase S. An enzymic function for erythrocuprein (hemocuprein). J Biol Chem 1969; 244:6049–6055
    [Google Scholar]
100. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333:664–666
     [Google Scholar]
101. Piacenza L, Trujillo M, Radi R. Reactive species and pathogen antioxidant networks during phagocytosis. J Exp Med 2019; 216:501–516 [View Article][PubMed]
     [Google Scholar]
102. Rawat M, Av-Gay Y. Mycothiol-dependent proteins in actinomycetes. FEMS Microbiol Rev 2007; 31:278–292
     [Google Scholar]
103. Pick N, Rawat M, Arad D, Lan J, Fan J et al. In vitro properties of antimicrobial bromotyrosine alkaloids. J Med Microbiol 2006; 55:407–415
     [Google Scholar]
104. KSE U, Av-Gay Y. Mycothiol-dependent mycobacterial response to oxidative stress. FEBS Lett 2006; 580:2712–2716
     [Google Scholar]
105. Newton GL, Av-Gay Y, Fahey RC. A novel mycothiol-dependent detoxification pathway in Mycobacteria involving mycothiol S -conjugate amidase. Biochemistry 2000; 39:10739–10746
     [Google Scholar]
106. Sao Emani C, Williams MJ, Van Helden PD, Taylor MJC, Wiid IJ et al. Gamma-glutamylcysteine protects ergothioneine-deficient Mycobacterium tuberculosis mutants against oxidative and nitrosative stress. Biochem Biophys Res Commun 2018; 495:174–178
     [Google Scholar]
107. Richard-Greenblatt M, Bach H, Adamson J, Pena-Diaz S, Wu L et al. Regulation of ergothioneine biosynthesis and its effect on Mycobacterium tuberculosis growth and infectivity. J Biol Chem 2015
     [Google Scholar]
108. Sao Emani C, Gallant JL, Wiid IJ, Baker B. The role of low molecular weight thiols in Mycobacterium tuberculosis . Tuberculosis 2019; 116:44–55
     [Google Scholar]
109. Vilchèze C, Av-Gay Y, Attarian R, Liu Z, Hazbón MH et al. Mycothiol biosynthesis is essential for ethionamide susceptibility in Mycobacterium tuberculosis . Mol Microbiol 2008; 69:1316–1329
     [Google Scholar]
110. Saini V, Cumming BM, Guidry L, Lamprecht DA, Adamson JH et al. Ergothioneine maintains redox and bioenergetic homeostasis essential for drug susceptibility and virulence of Mycobacterium tuberculosis . Cell Rep 2016; 0:
     [Google Scholar]
111. Ta P, Buchmeier N, Newton GL, Rawat M, Fahey RC. Organic hydroperoxide resistance protein and ergothioneine compensate for loss of mycothiol in Mycobacterium smegmatis mutants. J Bacteriol 2011; 193:1981–1990
     [Google Scholar]
112. Sao Emani C, Williams MJ, Wiid IJ, Baker B. The functional interplay of low molecular weight thiols in Mycobacterium tuberculosis . J Biomed Sci 2018; 25:55
     [Google Scholar]
113. Braunstein M, Espinosa BJ, Chan J, Belisle JT R, Jacobs Jr W. SecA2 functions in the secretion of superoxide dismutase A and in the virulence of Mycobacterium tuberculosis . Mol Microbiol 2003; 48:453–464
     [Google Scholar]
114. Nambi S, Long JE, Mishra BB, Baker R, Murphy KC et al. The Oxidative Stress Network of Mycobacterium tuberculosis Reveals Coordination between Radical Detoxification Systems. Cell Host Microbe 2015; 17:829–837
     [Google Scholar]
115. Middlebrook G. Isoniazid-resistance and catalase activity of tubercle bacilli; a preliminary report. Am Rev Tuberc 1954; 69:471–472
     [Google Scholar]
116. Timmins GS, Master S, Rusnak F, Deretic V. Nitric oxide generated from isoniazid activation by KatG: source of nitric oxide and activity against Mycobacterium tuberculosis . Antimicrob Agents Chemother 2004; 48:3006–3009
     [Google Scholar]
117. Jaeger T. Peroxiredoxin systems in mycobacteria. Subcell Biochem 2007; 44:207–217
     [Google Scholar]
118. Carabet LA, Guertin M, Lagüe P, Lamoureux G. Mechanism of the Nitric Oxide Dioxygenase Reaction of Mycobacterium tuberculosis Hemoglobin N. J Phys Chem B 2017; 121:8706–8718
     [Google Scholar]
119. Jaeger T, Flohé L. The thiol-based redox networks of pathogens: unexploited targets in the search for new drugs. Biofactors 2006; 27:109–120
     [Google Scholar]
120. Wong CF, Shin J, Subramanian Manimekalai MS, Saw WG, Yin Z et al. AhpC of the mycobacterial antioxidant defense system and its interaction with its reducing partner Thioredoxin-C. Sci Rep 2017; 7:5159
     [Google Scholar]
121. Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000; 405:962–966
     [Google Scholar]
122. Barry CE, Boshoff HIM, Dowd CS. Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis. Curr Pharm Des 2004; 10:3239–3262
     [Google Scholar]
123. Singh R, Manjunatha U, Boshoff HIM, YH H, Niyomrattanakit P et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 2008; 322:1392–1395
     [Google Scholar]
124. Kim S-Y, Park Y-J, Kim W-I, Lee S-H, Ludgerus Chang C et al. Molecular analysis of isoniazid resistance in Mycobacterium tuberculosis isolates recovered from South Korea. Diagn Microbiol Infect Dis 2003; 47:497–502
     [Google Scholar]
125. Piccaro G, Pietraforte D, Giannoni F, Mustazzolu A, Fattorini L. Rifampin induces hydroxyl radical formation in Mycobacterium tuberculosis . Antimicrob Agents Chemother 2014; 58:7527–7533
     [Google Scholar]
126. Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol 2002; 43:717–731
     [Google Scholar]
127. Gengenbacher M, SPS R, Pethe K, Dick T. Nutrient-starved, non-replicating Mycobacterium tuberculosis requires respiration, ATP synthase and isocitrate lyase for maintenance of ATP homeostasis and viability. Microbiology 2010; 156:81–87
     [Google Scholar]
128. Jain P, Weinrick BC, Kalivoda EJ, Yang H, Munsamy V et al. Dual-reporter Mycobacteriophages (Φ2DRMs) reveal preexisting Mycobacterium tuberculosis persistent cells in human sputum. mBio 2016; 7:e01023–16
     [Google Scholar]
129. Vilcheze C, Jacobs WRJ. The isoniazid paradigm of killing, resistance, and persistence in Mycobacterium tuberculosis . J Mol Biol 2019
     [Google Scholar]
130. Vilchèze C, Hartman T, Weinrick B, Jain P, Weisbrod TR et al. Enhanced respiration prevents drug tolerance and drug resistance in Mycobacterium tuberculosis . Proc Natl Acad Sci 2017; 114:4495–4500
     [Google Scholar]
131. Amaral EP, Conceição EL, Costa DL, Rocha MS, Marinho JM et al. N-acetyl-cysteine exhibits potent anti-mycobacterial activity in addition to its known anti-oxidative functions. BMC Microbiol 2016; 16:251
     [Google Scholar]
132. Fialkow L, Wang Y, Downey GP. Reactive oxygen and nitrogen species as signaling molecules regulating neutrophil function. Free Radic Biol Med 2007; 42:153–164
     [Google Scholar]
133. Al MH, Seo H, Kim S, Islam MI, Nam K-W et al. Thymoquinone (TQ) inhibits the replication of intracellular Mycobacterium tuberculosis in macrophages and modulates nitric oxide production. BMC Complement Altern Med 2017; 17:279
     [Google Scholar]
134. Balazy M, Kaminski PM, Mao K, Tan J, Wolin MS. S-Nitroglutathione, a product of the reaction between peroxynitrite and glutathione that generates nitric oxide. J Biol Chem 1998; 273:32009–32015
     [Google Scholar]
135. Venketaraman V, Talaue MT, Dayaram YK, Peteroy-Kelly MA, Bu W et al. Nitric oxide regulation of L-arginine uptake in murine and human macrophages. Tuberculosis 2003; 83:311–318
     [Google Scholar]
136. Machelart A, Song O-R, Hoffmann E, Brodin P. Host-directed therapies offer novel opportunities for the fight against tuberculosis. Drug Discov Today 2017; 22:1250–1257
     [Google Scholar]
137. Wipperman MF, Fitzgerald DW, Juste MAJ, Taur Y, Namasivayam S et al. Antibiotic treatment for tuberculosis induces a profound dysbiosis of the microbiome that persists long after therapy is completed. Sci Rep 2017; 7:10767
     [Google Scholar]
138. Tiberi S, du Plessis N, Walzl G, Vjecha MJ, Rao M et al. Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. Lancet Infect Dis 2018; 18:e183–198
     [Google Scholar]
139. Kolloli A, Subbian S. Host-Directed therapeutic strategies for tuberculosis. Front Med 2017; 4:171
     [Google Scholar]
140. Palucci I, Delogu G. Host directed therapies for tuberculosis: futures strategies for an ancient disease. Chemotherapy 2018; 63:172–180
     [Google Scholar]
141. Sorrentino F, Gonzalez del Rio R, Zheng X, Presa Matilla J, Torres Gomez P et al. Development of an intracellular screen for new compounds able to inhibit Mycobacterium tuberculosis growth in human macrophages. Antimicrob Agents Chemother 2016; 60:640–645
     [Google Scholar]
142. Richter A, Strauch A, Chao J, Ko M, Av-Gay Y. Screening of preselected libraries targeting Mycobacterium abscessus for drug discovery. Antimicrob Agents Chemother 2018; 62:e00828–18
     [Google Scholar]
143. Tobin DM. Host-Directed therapies for tuberculosis. Cold Spring Harb Perspect Med 2015; 5:
     [Google Scholar]
144. Stanley SA, Barczak AK, Silvis MR, Luo SS, Sogi K et al. Identification of host-targeted small molecules that restrict intracellular Mycobacterium tuberculosis growth. PLOS Pathog 2014; 10:e1003946
     [Google Scholar]
145. Korbee CJ, Heemskerk MT, Kocev D, van Strijen E, Rabiee O et al. Combined chemical genetics and data-driven bioinformatics approach identifies receptor tyrosine kinase inhibitors as host-directed antimicrobials. Nat Commun 2018; 9:358
     [Google Scholar]
146. Zhou J, Xu R, Du X-Z, Zhou X-D, Li Q. Saxifragifolin D attenuates phagosome maturation arrest in Mycobacterium tuberculosis-infected macrophages via an AMPK and VPS34-dependent pathway. AMB Express 2017; 7:11 [View Article][PubMed]
     [Google Scholar]
147. Crowle AJ, Douvas GS, May MH. Chlorpromazine: a drug potentially useful for treating mycobacterial infections. Chemotherapy 1992; 38:410–419
     [Google Scholar]
148. Kristiansen JE, Dastidar SG, Palchoudhuri S, Roy DS, Das S et al. Phenothiazines as a solution for multidrug resistant tuberculosis: from the origin to present. Int Microbiol 2015; 18:1–12
     [Google Scholar]
149. Juarez E, Carranza C, Sanchez G, Gonzalez M, Chavez J et al. Loperamide restricts intracellular growth of Mycobacterium tuberculosis in lung macrophages. Am J Respir Cell Mol Biol 2016; 55:837–847
     [Google Scholar]
150. Bruns H, Stegelmann F, Fabri M, Dohner K, van Zandbergen G et al. Abelson tyrosine kinase controls phagosomal acidification required for killing of Mycobacterium tuberculosis in human macrophages. J Immunol 2012; 189:4069–4078
     [Google Scholar]
151. Napier RJ, Rafi W, Cheruvu M, Powell KR, Zaunbrecher MA et al. Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis. Cell Host Microbe 2011; 10:475–485
     [Google Scholar]
152. Lachmandas E, Eckold C, Bohme J, Koeken V, Marzuki MB et al. Metformin alters human host responses to Mycobacterium tuberculosis in healthy subjects. J Infect Dis 2019
     [Google Scholar]
153. Naicker N, Sigal A, Naidoo K. Metformin as host-directed therapy for TB treatment: scoping review. Front Microbiol 2020; 11:435
     [Google Scholar]
154. Lougheed KEA, Taylor DL, Osborne SA, Bryans JS, Buxton RS. New anti-tuberculosis agents amongst known drugs. Tuberculosis 2009; 89:364–370
     [Google Scholar]
155. Shapira T, Rankine-Wilson L, Chao JD, Pichler V, Rens C et al. High-content screening of eukaryotic kinase inhibitors identify CHK2 inhibitor activity against Mycobacterium tuberculosis . Front Microbiol 2020; 11:
     [Google Scholar]
156. Festjens N, Vanden Berghe T, Vandenabeele P. Necrosis, a well-orchestrated form of cell demise: signalling cascades, important mediators and concomitant immune response. Biochim Biophys Acta - Bioenerg 1757; 2006:1371–1387
     [Google Scholar]
157. Tang D, Kang R, Coyne CB, Zeh HJ, Lotze MT. Pamps and DAMPs: signal’s that Spur autophagy and immunity. Immunol Rev 2012; 249:158–175 [View Article][PubMed]
     [Google Scholar]
158. Fink SL, Apoptosis CBT. Pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infect Immun 2005; 73:1907–1916
     [Google Scholar]
159. Molloy A, Laochumroonvorapong P, Kaplan G. Apoptosis, but not necrosis, of infected monocytes is coupled with killing of intracellular Bacillus Calmette-Guérin. J Exp Med 1994; 180:1499–1509
     [Google Scholar]
160. Butler RE, Brodin P, Jang J, Jang M-S, Robertson BD et al. The balance of apoptotic and necrotic cell death in Mycobacterium tuberculosis infected macrophages is not dependent on bacterial virulence. PLoS One 2012; 7:e47573
     [Google Scholar]
161. Thoma-Uszynski S, Stenger S, Takeuchi O, Ochoa MT, Engele M et al. Induction of direct antimicrobial activity through mammalian toll-like receptors. Science 2001; 291:1544–1547
     [Google Scholar]
162. Ashida H, Mimuro H, Ogawa M, Kobayashi T, Sanada T et al. Cell death and infection: a double-edged sword for host and pathogen survival. J Cell Biol 2011; 195:931 LP–942
     [Google Scholar]
163. Yang H, Chen J, Chen Y, Jiang Y, Ge B et al. Sirtuin inhibits M. tuberculosis -induced apoptosis in macrophage through glycogen synthase kinase-3β. Arch Biochem Biophys 2020; 694:108612
     [Google Scholar]
164. Friedrich A, Pechstein J, Berens C, Lührmann A. Modulation of host cell apoptotic pathways by intracellular pathogens. Curr Opin Microbiol 2017; 35:88–99
     [Google Scholar]
165. Davis JM, Ramakrishnan L. The role of the granuloma in expansion and dissemination of early tuberculous infection. Cell 2009; 136:37–49
     [Google Scholar]
166. Behar SM, Martin CJ, Booty MG, Nishimura T, Zhao X et al. Apoptosis is an innate defense function of macrophages against Mycobacterium tuberculosis . Mucosal Immunol 2011; 4:279–287
     [Google Scholar]
167. Dobos KM, Spotts EA, Quinn FD, King CH. Necrosis of lung epithelial cells during infection with Mycobacterium tuberculosis is preceded by cell permeation. Infect Immun 2000; 68:6300–6310
     [Google Scholar]
168. Watson RO, Manzanillo PS, Cox JS. Extracellular M. tuberculosis DNA targets bacteria for autophagy by activating the host DNA-sensing pathway. Cell 2012; 150:803–815 [View Article][PubMed]
     [Google Scholar]
169. Behar SM, Baehrecke EH. Tuberculosis: autophagy is not the answer. Nature 2015; 528:482–483
     [Google Scholar]
170. Etna MP, Sinigaglia A, Grassi A, Giacomini E, Romagnoli A et al. Mycobacterium tuberculosis-induced miR-155 subverts autophagy by targeting Atg3 in human dendritic cells. PLoS Pathog 2018; 14:e1006790
     [Google Scholar]
171. Fratazzi C, Arbeit RD, Carini C, Remold HG. Programmed cell death of Mycobacterium avium serovar 4-infected human macrophages prevents the mycobacteria from spreading and induces mycobacterial growth inhibition by freshly added, uninfected macrophages. J Immunol 1997; 158:4320–4327
     [Google Scholar]
172. Hu W, Chan H, Lu L, Wong KT, Wong SH et al. Autophagy in intracellular bacterial infection. Semin Cell Dev Biol 2020; 101:41–50
     [Google Scholar]
173. Singhal A, Jaiswal A, Arora VK, Prasad HK. Modulation of gamma interferon receptor 1 by Mycobacterium tuberculosis: a potential immune response evasive mechanism. Infect Immun. 2007/03/05 2007; 75:2500–2510
     [Google Scholar]
174. Schiebler M, Brown K, Hegyi K, Newton SM, Renna M et al. Functional drug screening reveals anticonvulsants as enhancers of mTOR-independent autophagic killing of Mycobacterium tuberculosis through inositol depletion. EMBO Mol Med 2015; 7:127–139
     [Google Scholar]
175. Lee H-J, H-J K, Kim SH, Jung Y-J. Pasakbumin a controls the growth of Mycobacterium tuberculosis by enhancing the autophagy and production of antibacterial mediators in mouse macrophages. PLoS One 2019; 14:e0199799
     [Google Scholar]
176. Bento CF, Empadinhas N, Mendes V. Autophagy in the fight against tuberculosis. DNA Cell Biol. 2015/01/21 2015; 34:228–242
     [Google Scholar]
177. Cambier CJ, Falkow S, Ramakrishnan L. Host Evasion and Exploitation Schemes of Mycobacterium tuberculosis . Cell 2014; 159:1497–1509
     [Google Scholar]
178. Lam A, Prabhu R, Gross CM, Riesenberg LA, Singh V et al. Role of apoptosis and autophagy in tuberculosis. Am J Physiol Lung Cell Mol Physiol 2017; 313:L218–229
     [Google Scholar]
179. Queval CJ, Brosch R, Simeone R. The macrophage: a disputed fortress in the battle against Mycobacterium tuberculosis . Front Microbiol 2017; 8:2284
     [Google Scholar]
180. Paik S, Kim JK, Chung C, E-K J. Autophagy: a new strategy for host-directed therapy of tuberculosis. Virulence 20181–12
     [Google Scholar]
181. Kim J-J, Lee H-M, Shin D-M, Kim W, Yuk J-M et al. Host cell autophagy activated by antibiotics is required for their effective antimycobacterial drug action. Cell Host Microbe 2012; 11:457–468
     [Google Scholar]
182. Wong D, Chao JD, Av-Gay Y. Mycobacterium tuberculosis-secreted phosphatases: from pathogenesis to targets for TB drug development. Trends Microbiol 2013; 21:100–109
     [Google Scholar]
183. Welin A, Eklund D, Stendahl O, Lerm M. Human macrophages infected with a high burden of ESAT-6-expressing M. tuberculosis undergo caspase-1- and cathepsin B-independent necrosis. PLoS One 2011; 6:e20302
     [Google Scholar]
184. Augenstreich J, Arbues A, Simeone R, Haanappel E, Wegener A et al. Esx-1 and phthiocerol dimycocerosates of Mycobacterium tuberculosis act in concert to cause phagosomal rupture and host cell apoptosis. Cell Microbiol 2017; 19:
     [Google Scholar]
185. Singh B, Cocker D, Ryan H, Sloan DJ. Linezolid for drug-resistant pulmonary tuberculosis. Cochrane Database Syst Rev 2019; 3:CD012836 [View Article][PubMed]
     [Google Scholar]
186. Singhal A, Jie L, Kumar P, Hong GS, Leow MK-S et al. Metformin as adjunct antituberculosis therapy. Sci Transl Med 2014; 6:
     [Google Scholar]
187. Andersen P, Andersen AB, Sorensen AL, Nagai S. Recall of long-lived immunity to Mycobacterium tuberculosis infection in mice. J Immunol 1995; 154:3359–3372
     [Google Scholar]
188. Brodin P, de Jonge MI, Majlessi L, Leclerc C, Nilges M et al. Functional analysis of early secreted antigenic target-6, the dominant T-cell antigen of Mycobacterium tuberculosis, reveals key residues involved in secretion, complex formation, virulence, and immunogenicity. J Biol Chem 2005; 280:33953–33959
     [Google Scholar]
189. Houben D, Demangel C, van Ingen J, Perez J, Baldeón L et al. ESX-1-mediated translocation to the cytosol controls virulence of mycobacteria. Cell Microbiol 2012; 14:1287–1298
     [Google Scholar]
190. Venketaraman V, Dayaram YK, Amin AG, Ngo R, Green RM et al. Role of glutathione in macrophage control of mycobacteria. Infect Immun 2003; Apr 1;71:1864 LP–1871
     [Google Scholar]
191. Pérez E, Samper S, Bordas Y, Guilhot C, Gicquel B et al. An essential role for phoP in Mycobacterium tuberculosis virulence. Mol Microbiol 2001; 41:179–187
     [Google Scholar]
192. Wong D, Li W, Chao JD, Zhou P, Narula G et al. Protein tyrosine kinase, PtkA, is required for Mycobacterium tuberculosis growth in macrophages. Sci Rep 2018; 8:1–12
     [Google Scholar]
193. Zulauf KE, Sullivan JT, Braunstein M. The SecA2 pathway of Mycobacterium tuberculosis exports effectors that work in concert to arrest phagosome and autophagosome maturation. PLOS Pathog 2018; 14:e1007011
     [Google Scholar]
194. Edwards KM, Cynamon MH, Volari RKR, Hager CC, DeStefano MS et al. Iron-cofactored Superoxide Dismutase Inhibits Host Responses to Mycobacterium tuberculosis . Am J Respir Crit Care Med 2001; 164:2213–2219
     [Google Scholar]
195. Kroesen VM, Rodríguez-Martínez P, García E, Rosales Y, Díaz J et al. A beneficial effect of low-dose aspirin in a murine model of active tuberculosis. Front Immunol 2018; 9:798
     [Google Scholar]
196. Bezabeh T, Mowat MR, Jarolim L, Greenberg AH, Smith IC. Detection of drug-induced apoptosis and necrosis in human cervical carcinoma cells using 1H NMR spectroscopy. Cell Death Differ 2001; 8:219–224
     [Google Scholar]
197. Juárez E, Carranza C, Sánchez G, González M, Chávez J et al. Loperamide restricts intracellular growth of Mycobacterium tuberculosis in lung macrophages. Am J Respir Cell Mol Biol 2016; 55:837–847
     [Google Scholar]
198. KKY L, Zheng X, Forestieri R, Balgi AD, Nodwell M et al. Nitazoxanide stimulates autophagy and inhibits mTORC1 signaling and intracellular proliferation of Mycobacterium tuberculosis . PLoS Pathog 2012; 8:e1002691
     [Google Scholar]
199. Williams DE, Dalisay DS, Chen J, Polishchuck EA, Patrick BO et al. Aminorifamycins and sporalactams produced in culture by a Micromonospora sp. isolated from a Northeastern-Pacific marine sediment are potent antibiotics. Org Lett 2017; 19:766–769
     [Google Scholar]
200. Serebryakova VA, Urazova OI, Novitsky VV, Vengerovskii AI, Kononova TE et al. Effects of levofloxacin on blood lymphocyte apoptosis in patients with pulmonary tuberculosis: an in vitro study. Bull Exp Biol Med 2019; 168:109–112 [View Article]
     [Google Scholar]
201. Floto RA, Sarkar S, Perlstein EO, Kampmann B, Schreiber SL et al. Small molecule enhancers of rapamycin-induced TOR inhibition promote autophagy, reduce toxicity in Huntington’s disease models and enhance killing of mycobacteria by macrophages. Autophagy 2007; 3:620–622 [View Article]
     [Google Scholar]